Publications by authors named "H J Stellbrink"
Effectiveness, safety, and patient-reported outcomes of emtricitabine/tenofovir alafenamide-based regimens for the treatment of HIV-1 infection: Final 24-month results from the prospective German TAFNES cohort study.
HIV Med
October 2024
Background: Tenofovir alafenamide (TAF) was introduced in the European Union in 2015 as a novel prodrug of tenofovir showing similar efficacy in clinical trials and a more favorable safety profile than tenofovir disoproxil fumarate (TDF). The German TAFNES cohort study (2016-2019) was conducted to generate real-world evidence.
Methods: Treatment-naïve (TN) and treatment-experienced (TE) people with HIV (PWH) receiving elvitegravir/cobicistat/emtricitabine/TAF (E/C/F/TAF), rilpivirine/F/TAF (R/F/TAF) or F/TAF + 3rd agent were included.
Article Synopsis
- The NEAT022 trial found that switching from boosted protease inhibitors to dolutegravir in people with HIV and high cardiovascular risk led to positive changes in various cardiovascular-related biomarkers over 96 weeks.
- Out of 415 participants, significant improvements were observed in biomarkers linked to inflammation, immune activation, and myocardial injury, despite a concerning reduction in adiponectin, indicating higher insulin resistance.
- However, no significant differences in carotid intima-media thickness progression were detected between the treatment groups.
Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 Trial.
Clin Infect Dis
October 2023
Article Synopsis
- - Participants with HIV at high cardiovascular risk who switched to dolutegravir showed no significant difference in hypertension incidence compared to those who continued protease inhibitors over 96 weeks.
- - Both groups experienced a small but significant increase in diastolic blood pressure during the first 48 weeks after switching to dolutegravir.
- - Factors like existing health conditions, rather than the treatment itself, were more closely linked to the development of hypertension in the study participants.
Background: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is a single-tablet regimen recommended for HIV-1 treatment. The safety and efficacy of B/F/TAF as initial therapy was established in two Phase 3 studies: 1489 (vs dolutegravir [DTG]/abacavir/lamivudine) and 1490 (vs DTG + F/TAF). After 144 weeks of randomized follow-up, an open-label extension evaluated B/F/TAF to 240 weeks.
View Article and Find Full Text PDFBackground & Aims: EASL guidelines recommend 8 weeks of treatment with sofosbuvir plus velpatasvir (SOF/VEL) for the treatment of acute or recently acquired HCV infection, but only 6- and 12-week data are available. Therefore, the aim of this study was to evaluate the safety and efficacy of a shortened 8-week SOF/VEL treatment for acute HCV monoinfection.
Methods: In this investigator-initiated, prospective, multicentre, single-arm study, we recruited 20 adult patients with acute HCV monoinfection from nine centers in Germany.